Abstract: A therapeutic agent for alleviating disorders caused by nerve cell degeneration in the brain which contains a cyclopropachromen derivative represented by the following general formula (I): ##STR1## wherein n is an integer of from 2 to 5;the carbon atom in the --(CH.sub.2).sub.n -- moiety may be optionally substituted with a methyl group or a hydroxyl group;R.sup.1 and R.sup.2 independently represent a hydrogen atom, an alkyl group having 1 to 5 carbon atoms, a phenyl group or an aralkyl group having 7 to 10 carbon atoms; or alternatively R.sup.1 and R.sup.2 form together with the nitrogen atom to which they are attached, a morpholino group, a thiomorpholino group, a pyrrolidinyl group, a piperidinyl group, a homopiperidinyl group, a piperazinyl group, a homopiperazinyl group, an N-alkylpiperazinyl group, N-alkylhomopiperazinyl group, an N-hydroxyalkylpiperazinyl group or a pyrrolidonyl group or alternatively R.sup.1 and R.sup.
Abstract: Excitatory amino acid receptor antagonists and methods for the use thereof are disclosed. The antagonists include compounds having the preferred formula: ##STR1## in which: each of A.sub.1, A.sub.2 and A.sub.3 is independently either C or N, except that at least one of A.sub.1, A.sub.2 and A.sub.3 is N; one of A.sub.4 and A.sub.5 is C and the other is N; each R.sub.1 and R.sub.2 is independently hydrogen, halogen, CN, NO.sub.2, alkyl, aromatic, azido or CF.sub.3 ; and R.sub.3 is hydrogen, alkyl, aromatic or CF.sub.3. Also included are the tautomers thereof, and the pharmaceutically acceptable salts of (III) and (IV) and the tautomers thereof. These compounds are useful as EAA antagonists for blocking one or more EAA receptors, as neurological disorders associated with EAA receptors.
Type:
Grant
Filed:
June 5, 1991
Date of Patent:
October 6, 1992
Assignee:
Eli Lilly and Company
Inventors:
Loretta A. McQuaid, Charles H. Mitch, Paul L. Ornstein, Darryle D. Schoepp, Edward C. R. Smith
Abstract: The known compound 1,2,3,9-tetrahydro-9-methyl-3-[(2-methyl-1H-imidazol-1-yl)methyl]4H-carbaz ol-4-one, which is available commercially as the dihydrate of its hydrochloride acid addition salt, is useful for the treatment of chest pain not associated with a cardial or esophageal structural abnormality, e.g., esophagael immobility.
Abstract: The present invention is related to a pharmaceutical composition suitable for the treatment of schizophrenia comprising an acid addition salt of (1)-N-(1-phenyl-isopropyl)-N-methyl-1-propynyl-amine in a therapeutically effective amount and optionally one or more neuroleptica and pharmaceutically acceptable carriers, and other excipients.
Type:
Grant
Filed:
June 18, 1990
Date of Patent:
September 29, 1992
Assignee:
Chinoin Gyogyszer- es Vegyeszeti Termekek Gyara Rt.
Inventors:
Andras Perenyi, Goswami Utpal, Mihaly Arato, Ede Frescka, Jozsef Knoll, D. Arpad Bela
Abstract: A method of resisting neurological damage caused by overstimulation of the NMDA receptor of nerve cells by glutamate includes exposing the NMDA receptors to an oxidizing agent to thereby diminish overall activity of the receptors following activation by glutamate. The oxidizing agent preferably is a material selected from the group consisting of pyrroloquinoline quinone and topa hydantoin.
Type:
Grant
Filed:
September 12, 1991
Date of Patent:
September 8, 1992
Assignee:
University of Pittsburgh of the Commonwealth System of Higher Education
Inventors:
Elias Aizenman, Paul A. Rosenberg, Paul M. Gallop
Abstract: A preparation for the treatment and prevention of thromboses and thromboembolic complications is disclosed, which preparation has a content of protein S at a concentration at least 50 times that present in native plasma and is free from C4b-binding protein, optionally in combination with a content of activated protein C.
Type:
Grant
Filed:
June 19, 1990
Date of Patent:
September 1, 1992
Assignee:
Immuno Aktiengesellschaft
Inventors:
Hans P. Schwarz, Ewald Molinari, Yendra Linnau, Susanne Pfeiler
Abstract: This invention relates to a novel composition for attracting mullein bugs, Campylomma verbasci, a pest of tree fruit orchards in North America. The invention also pertains to methods of attracting mullein bugs and predicting future population levels of these insects. The composition for attracting male mullein bugs, Campylomma verbasci, comprises a mixture of butyl butyrate and 2 (E)-crotyl butyrate.
Type:
Grant
Filed:
November 30, 1990
Date of Patent:
September 1, 1992
Assignee:
Phero Tech Inc.
Inventors:
Robert F. Smith, Harold D. Pierce, Jr., John H. Borden, Leslie J. Chong, Nairn W. Hay
Abstract: Microparticles which are less than 12 .mu.m in size and are formed of or comprise a solid lipophilic group-containing compound having an HLB value less than about 20 produce a long lived ultrasonically echogenic entity in aqueous liquid and are useful as left heart ultrasonic contrast image enhancing agents. Contrast media for ultrasonic diagnostics comprising a liquid vehicle containing (a) suspended therein microparticles of a mixture of at least one (C.sub.8 -C.sub.20)-fatty acid and at least one solid that is not a surfactant and (b) microbubbles, are especially effective upon ultrasonic imaging after intravenous administration, for the contrasting of both the right heart and left heart, of the myocardium, as well as other organs, such as liver, spleen, and kidneys.
Type:
Grant
Filed:
March 18, 1991
Date of Patent:
August 25, 1992
Assignee:
Schering Aktiengesellschaft
Inventors:
Ned S. Rasor, Jurgen Hilmann, Lothar Lange, Thomas Fritzsch, Joachim Siegert, Ingfried Zimmermann
Abstract: Zinc acexamate acts by increasing the synthesis of mucus, reinforces the mucous barrier, improves the microcirculation and increases the synthesis of prostaglandins in the gastric mucous membrane, whereby it is effective in the treatment of said gastropathy, contrary to the results obtained with antiacids or antisecretory agents.
Abstract: A method for relieving depression with decahydro-3-[4-[4-(2-pyrimidinyl)-1-piperazinyl]butyl]-1,5-methano-6,7,9-m etheno-2H-pentaleno[1,2-d]azepine-2,4(3H)-dione, or a pharmaceutically acceptable salt thereof.
Abstract: Treating a patient for neuro-muscular incontinence by administering a thiol-S-(2-diethyl-aminoethyl)-ester compound selected from the group consisting of trimethylacetyl-thio-S-(2-diethylaminoethyl)-ester, 1-cyclohexyl-1-phenylacetyl-thiol-S-(2-diethylaminoethyl)-ester, palmitoyl-thio-S-(2-diethylaminoethyl)-ester, 4-t-butyl-benzoyl-thiol-S-(2-diethylaminoethyl)-ester, phenylacetyl-thio-S-(2-diethylaminoethyl)-ester, 4-phenyl-butyryl-thio-S-(2-diethylaminoethyl)-ester, and 2-ethyl-butyryl-thio-S-(2-diethylaminoethyl)-ester.
Abstract: A method is provided for preventing or reducing the risk of or treating Type II diabetes by administering a cholesterol lowering drug, such as pravastatin, alone or in combination with an ACE inhibitor, such as captopril, zofenopril, ceranapril, fosinopril, enalapril or lisinopril.
Abstract: A method of treating a chemical dependency in a mammal, comprising administering to a mammal in need of such treatment an amount of the compound (1S-cis)-4-(3, 4-dichlorophenyl)-1,2,3,4-tetraahydro-N-methyl-1-naphthalenamine, also known by the generic name sertraline, or a pharmaceutically acceptable salt thereof, effective in reducing or alleviating such dependency.
Type:
Grant
Filed:
February 28, 1991
Date of Patent:
July 14, 1992
Assignee:
Pfizer Inc.
Inventors:
Nicholas G. Bacopoulos, Peter A. Blick, B. Kenneth Koe, Evan R. Norris
Abstract: A method of preventing or alleviating certain conditions by administering to a human or an animal a pharmaceutical composition comprising an amount of at least one specific isomer of inositol trisphosphate sufficient to obtain said prevention or alleviation.
Type:
Grant
Filed:
September 11, 1990
Date of Patent:
July 7, 1992
Assignee:
Perstorp AB
Inventors:
Matti Siren, Bertil Lofkvist, Lars Edvinsson
Abstract: A method for improvement of excretion of nonprotein nitrogen into the intestines which comprises administering, to a subject in need of such improvement, a prostanoic acid derivative in an amount effective in improving excretion of nonprotein nitrogen into the intestines.
Abstract: An external analgesic lotion containing active ingredients of camphor and menthol to relieve pain in muscles, joints, or viscera distal at the site of application by stimulating cutaneous sensory receptors and a method of making such lotion and being made from camphor and menthol crystals.
Abstract: Certain anticonvulsant drugs have been found to be effective in the treatment of motion sickness. These compounds have the structure: ##STR1## wherein R.sub.1, R.sub.2 and R.sub.3 are H, aliphatic or aromatic groups;B is --C.dbd.O or --CH.sub.2 --;n is 0 or 1;X is ##STR2## and their non-toxic, pharmaceutically-acceptable acid addition salt.